Themis Medicare Ltd P/E Ratio

The P/E Ratio of Themis Medicare Ltd is 54.3 as of 25 Jul 9.00 AM .a1#The P/E Ratio of Themis Medicare Ltd changed from 8.9 on March 2019 to 46.3 on March 2024 . This represents a CAGR of 39.07% over 5 years. a1#The Latest Trading Price of Themis Medicare Ltd is ₹ 248.65 as of 25 Jul 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.3 to 27.3 in 5 years. This represents a CAGR of -0.72%a1# The PE Ratio of Automobile industry is 18.9. The PE Ratio of Finance industry is 23.5. The PE Ratio of IT - Software industry is 29.1. The PE Ratio of Pharmaceuticals industry is 38.6. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 24.3. In 2024a1#The Market Cap of Themis Medicare Ltd changed from ₹ 272.17 crore on March 2019 to ₹ 2015 crore on March 2024 . This represents a CAGR of 39.61% over 6 years. a1#The Revenue of Themis Medicare Ltd changed from ₹ 100.89 crore to ₹ 102.49 crore over 8 quarters. This represents a CAGR of 0.79% a1#The EBITDA of Themis Medicare Ltd changed from ₹ 26.81 crore to ₹ 13.97 crore over 8 quarters. This represents a CAGR of -27.81% a1#The Net Pr of Themis Medicare Ltd changed from ₹ 17.4 crore to ₹ 6.64 crore over 8 quarters. This represents a CAGR of -38.23% a1#The Dividend Payout of Themis Medicare Ltd changed from 10.11 % on March 2019 to 18.59 % on March 2024 . This represents a CAGR of 12.96% over 5 years. a1#

Incorporated in 1969, Themis Medicare Ltd., formerly known as Themis Chemicals (TCL) was originally promoted by Chemosyn and Medimpex but was taken over by a Group consisting of Shantibhai D Patel and K T Lakdawala who also have interests in Andhra Synthetics and Antibiotics, which was merged with Artemis Pharmaceuticals in April 93. The Group is principally engaged in the activities pertaining to manufacturing of pharmaceutical products, especially in Formulation and API activity. In Mar.'95, the company came out with a public issue equity shares (premium : Rs 110) to finance the expansion-cum-modernisation of its synthetic bulk drug plant at Vapi, the setting up of a formulation unit at Lilora, Baroda as backward integration and to augment long-term working capital. Total cost of the project was estimated at Rs 17.64 cr. TCL manufactures and sells synthetic bulk drugs and formulations. It operates in the therapeutic segments of anti-tuberculosis, cerebroactivators, bronchodilators, anti-asthmatic, anaesthetic and other segments. Anti-tuberculosis bulk drugs and formulations account for 60% of its turnover and the company is rated fourth in terms of turnover in this segment. TCL has also started manufacturing and exporting fumagillin, an anti-bacterial drug, for veterinary use for which it has a confirmed buy-back arrangement with Chinoin, Hungary. The company with the help of M/s Pharmograd,Moscow a manufacturing unit, is planning to market its Anti-T.B.formulation products through the collborators throughout the Russian Federation for trade,tenders and govt.supplies. The Company introduced products like Cardiac and Muscular Relaxant during the year 2001-02. A wholly owned subsidiary of the Company, Themis Medicare Singapore Pte. Ltd., formed on 22nd May, 2002 in Singapore became operational during the year 2002-03. M/s. Artemis Biotech Ltd., a Group Company was merged with Themis Medicare Ltd. (the Parent Company) with effect from 1st April 2003. The Joint Venture Company, 'Richter Themis Medicare (India) Pvt. Ltd.' started manufacturing activities at its EOU unit at Vapi effective from March, 2006. The Company started operations of its new Injection Plant at Haridwar for tablets and gel formulation production in 2006-07. 'Themiseal', the Company's unique haemostatic and anti-microbial product was launched in the UK, Greece, Cyprus, Jordan, Romania and Indonesia. During the year 2010-11, a Private Ltd Subsidiary Company in the name and style of Themis Lifestyle Pvt. Ltd was incorporated on 3rd November, 2010 and another Public Ltd Subsidiary Company in the name and style of Artemis Biotech Ltd. was incorporated on 14th January, 2011. During FY 2016-17, HID-PUL KFT (Hungary), a Wholly Owned Subsidiary of the Company, ceased to be a subsidiary of the Company. 'Carpo Medical Limited' was incorporated as a Joint Venture Company in the United Kingdom in 2016-17.